Solanki Pawan K, Yellapragada Samir, Lynch Brendan, Eibel Maria, Viscusi Eugene R, Emerick Trent
Department of Anesthesiology and Perioperative Medicine, Chronic Pain Division, UPMC, Pittsburgh, Pennsylvania, USA
Department of Anesthesiology and Perioperative Medicine, Chronic Pain Division, UPMC, Pittsburgh, Pennsylvania, USA.
Reg Anesth Pain Med. 2025 Jan 7;50(1):55-58. doi: 10.1136/rapm-2023-105190.
This paper explores the rapid emergence of xylazine exposure in the USA and its implications for anesthesiologists. Xylazine, a non-opioid sedative and analgesic often used in veterinary medicine, has increasingly been found as an adulterant in the illicit substance supply, leading to serious health implications. The pharmacological properties of xylazine, its clinical effects, and the challenges it poses for clinicans will be discussed. Perioperative strategies for anesthesiologists to manage these potential cases are provided. Furthermore, this paper necessitates an epidemiological understanding for detection and multidisciplinary collaboration in addressing this emerging public health threat. The manuscript concludes by emphasizing the role anesthesiologists will have to play in managing the clinical implications of xylazine and contributing to public health strategies aimed at curbing its misuse.
本文探讨了赛拉嗪在美国迅速出现的情况及其对麻醉医生的影响。赛拉嗪是一种常用于兽医学的非阿片类镇静和镇痛药,越来越多地被发现是非法药物供应中的掺杂物,会导致严重的健康问题。本文将讨论赛拉嗪的药理特性、临床效果及其给临床医生带来的挑战。还将为麻醉医生提供应对这些潜在病例的围手术期策略。此外,本文还需要从流行病学角度了解如何检测这种药物,并通过多学科合作来应对这一新兴的公共卫生威胁。本文在结尾强调了麻醉医生在应对赛拉嗪的临床影响以及为旨在遏制其滥用的公共卫生策略做出贡献方面将发挥的作用。